Jan 29, 2025 · AB Science to launch new Phase 3 trial of masitinib for ALS. AB Science will launch a new Phase 3 clinical trial to test its investigational oral therapy masitinib in people with amyotrophic lateral sclerosis (ALS) whose disease is progressing normally and who haven’t completely lost physical function, according to a company update.

Dec 30, 2024 · Read this story here. No. 8 – COYA 302 immune-modulating therapy shows promise in small early trial. Coya Therapeutics’ investigational therapy COYA 302 was found to slow ALS disease progression and lower levels of disease-related biomarkers in a small Phase 1 clinical trial. COYA 302 is a combination of an immune signaling molecule called interleukin-2 and a fusion protein called CTLA4-Ig ...

AB Science to launch new Phase 3 trial of masitinib for ALS. AB Science will launch a new Phase 3 clinical trial to test its investigational oral therapy masitinib in people with amyotrophic lateral sclerosis (ALS) whose disease is progressing normally and who haven’t completely lost physical function, according to a company update.

Jan 31, 2025 · Evaluating masitinib in ALS. A previous Phase 2/3 clinical trial (NCT02588677) tested two daily doses of masitinib (3 or 4.5 mg/kg) against a placebo in nearly 400 adults with ALS. The treatment was administered as an add-on to the approved ALS therapy Rilutek (riluzole) for nearly a year, or 48 weeks.. The study mainly sought to evaluate changes in disease progression, as assessed by the ALS ...

Jan 21, 2025 · Qalsody (tofersen) halted disease progression and improved functional independence and mobility in people with amyotrophic lateral sclerosis (ALS) who received the treatment in a real-world setting, according to a study involving seven patients carrying mutations in the SOD1 gene.

Jan 8, 2025 · The number of people living with amyotrophic lateral sclerosis (ALS) in the U.S. is expected to steadily climb — by more than 10% — over this decade, increasing from an estimated 32,800 cases in 2022 to about 36,300 in 2030, according to a new study from researchers with the Centers for Disease Control and Prevention (CDC).

Jan 13, 2025 · Alchemab, a U.K.-based company, has been looking for naturally occurring antibodies that may confer disease protection to some individuals. The company first identifies people who are more resilient to a given condition, and then sequences their immune B-cells (the cells responsible for making antibodies) to look for related antibodies that are common in that population but absent in people ...

1 day ago · Effect of TBI on SOD1 mutations. Here, scientists at the University of Massachusetts Chan Medical School investigated the impact of repetitive TRI in a mouse model of SOD1-ALS to see if it accelerates the onset and progression of ALS in people carrying SOD1 mutations, which are seen in about 20% of familial ALS and 2% of sporadic cases.. The researchers also bred ALS mice lacking Sarm1, a gene ...

3 days ago · Studies in cellular and animal models found the candidate treatment, JRMS-22, prevented or reversed the TDP-43 protein clumps that damage nerve cells.TDP-43 accumulation in neurons is found in about 97% of all with ALS, whether a person has familial ALS and sporadic disease.. LifeArc scientists and its drug discovery assays will assist Neuropeutics in …

Jan 2, 2024 · No. 9 – Further questions set back European approval of AMX0035. Amylyx Pharmaceuticals’ application seeking the approval of AMX0035 in treating ALS patients across Europe faced a second round of questions from the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency. The committee still had major objections to AMX0035 that needed to be addressed ...